BioXcel Therapeutics, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 555 LONG WHARF DRIVE, NEW HAVEN, CT, 06511
Mailing Address 555 LONG WHARF DRIVE, NEW HAVEN, CT, 06511
Phone 203-643-8060
Fiscal Year End 1231
EIN 821386754
Financial Overview
FY2024
-$179.05M
Net Income
$131.44M
Total Liabilities
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | February 12, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 9, 2026 | View on SEC |
| 8-K Current report of material events | February 6, 2026 | View on SEC |
| 8-K Current report of material events | January 20, 2026 | View on SEC |
| 4 Insider stock transaction report | January 12, 2026 | View on SEC |
| 8-K Current report of material events | January 12, 2026 | View on SEC |
| 4 Insider stock transaction report | January 12, 2026 | View on SEC |
| 4 Insider stock transaction report | January 12, 2026 | View on SEC |
| 4 Insider stock transaction report | January 12, 2026 | View on SEC |
| 4 Insider stock transaction report | January 12, 2026 | View on SEC |
Material Events
8-K Strategy Change February 12, 2026
High Impact
- IGALMI®'s at-home use targets a multi-billion dollar market opportunity, with up to 1.8 million potentially eligible patients.
- Physicians show high interest, with 70% likely to prescribe at-home IGALMI® for at least 70% of eligible patients.
8-K Strategy Change February 6, 2026
High Impact
- Executive bonuses align leadership with critical strategic goals, including potential M&A or capital raise.
- IGALMI®'s sNDA for at-home use could open a significant new market as the first FDA-approved treatment.
8-K Strategy Change January 12, 2026
High Impact
- BioXcel Therapeutics is launching a new commercial push for IGALMI™ for potential at-home use.
- Mark Pavao has been hired as Interim Chief Commercial Officer to lead the at-home market expansion.
8-K Strategy Change December 15, 2025
High Impact
- BioXcel Therapeutics, Inc. shareholders approved a reverse stock split.
- The primary purpose of the reverse stock split is to regain compliance with the Nasdaq Capital Market's minimum bid price requirements to avoid delisting.
Related Companies
Companies in the same industry (SIC: 2834)
Werewolf Therapeutics, Inc.
HOWL Pharmaceutical Preparations
Zenas BioPharma, Inc.
ZBIO Pharmaceutical Preparations
Centessa Pharmaceuticals plc
CNTA Pharmaceutical Preparations
Karyopharm Therapeutics Inc.
KPTI Pharmaceutical Preparations
VERTEX PHARMACEUTICALS INC / MA
VRTX Pharmaceutical Preparations
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.